WO2021260516A1 - An organic amine salt of favipiravir and a process for the purification of favipiravir - Google Patents
An organic amine salt of favipiravir and a process for the purification of favipiravir Download PDFInfo
- Publication number
- WO2021260516A1 WO2021260516A1 PCT/IB2021/055425 IB2021055425W WO2021260516A1 WO 2021260516 A1 WO2021260516 A1 WO 2021260516A1 IB 2021055425 W IB2021055425 W IB 2021055425W WO 2021260516 A1 WO2021260516 A1 WO 2021260516A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- favipiravir
- organic amine
- purification
- salt
- amine salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to an organic amine salt of Favipiravir. Further, the present invention also relates to a process for the purification of Favipiravir.
- Favipiravir is an anti-viral agent that selectively and potently inhibits the viral RNA-dependent RNA polymerase (RdRp). It is known under the chemical name 6-fluoro-3-hydroxy-2- pyrazinecarboxamide. Favipiravir is a compound which is useful for the treatment, such as prevention or therapy, of a viral infection or, particularly, an influenza viral infection. Favipiravir and a process for its preparation were first disclosed in W02000010569.
- the main objective of the present invention is to provide an organic amine salt of Favipiravir.
- Another objective of the present invention is to provide a process for the purification of Favipiravir.
- the present invention provides an organic amine salt of Favipiravir.
- the present invention provides a process for the purification of Favipiravir comprising the steps of: a) treating crude Favipiravir with a suitable organic amine in the presence of a suitable solvent to form a corresponding organic amine salt of Favipiravir; b) isolating the organic amine salt of Favipiravir; c) treating the organic amine salt of Favipiravir of step (b) with a suitable acid to afford highly pure Favipiravir.
- the organic amine is selected from tertiary amines such as trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and /V,/V-dimethylcyclohexylamine; secondary amines such as dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, /V-benzylmethylamine and dicyclohexylamine; primary amines such as methylamine, ethylamine, propylamine, butylamine, benzylamine, aniline, pyrrolidine, pyridine; and the like.
- tertiary amines such as trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and /V,/V-dimethylcyclohexylamine
- secondary amines such as
- the organic amine is selected from dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, N- benzylmethylamine and dicyclohexylamine.
- the suitable solvent is selected from aliphatic, alicyclic or aromatic halogenated hydrocarbons such as chlorobenzene, dichlorobenzene, dichloromethane, chloroform, tetrachloromethane, dichloroethane or trichloroethane; aromatic hydrocarbon like toluene; ethers such as diethylether, diisopropyl ether, methyl tert- butyl ether, methyl tert- amyl ether, dioxane, tetrahydrofuran, 1,2- dimethoxy ethane, 1 ,2-diethoxy ethane or anisole; nitriles such as acetonitrile, propionitrile, n- or iso-butyronitrile or benzonitrile; amides such as /V,/V-dimethylformamide, N,N- dimethylacetamide, /V- methyl formanilide, /V-methylpyrrol
- the suitable acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid and the like.
- the purity of the crude Favipiravir is in the range of 95 to 99 %.
- the purity of the obtained purified Favipiravir is in the range of 99.5 to 99.9 %.
- compositions comprising, “comprising”, “includes”, “including”, “has”, “having”, “contains”, “containing”, “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated.
- a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.
- the present invention provides an organic amine salt of Favipiravir.
- the organic amine salt of the Favipiravir can be produced by subjecting Favipiravir to a reaction with an organic amine. This reaction is usually carried out in the presence of a suitable solvent. All types of solvents can be used for the reaction provided that their presence is not detrimental to the reaction in any way.
- the present invention provides a dicyclohexylamine salt of Favipiravir.
- the present invention provides a morpholine salt of Favipiravir.
- the present invention provides a process for the synthesis of an organic amine salt of Favipiravir, which comprises treating Favipiravir with a suitable organic amine, in the presence of a suitable solvent to afford an organic amine salt of Favipiravir.
- the present invention provides a process for the purification of Favipiravir comprising the steps of: a) treating crude Favipiravir with a suitable organic amine in the presence of a suitable solvent to form a corresponding organic amine salt of Favipiravir; b) isolating the organic amine salt of Favipiravir; c) treating the organic amine salt of Favipiravir of step (b) with a suitable acid to afford highly pure Favipiravir, wherein the purity of the obtained purified Favipiravir is in the range of 99.5 to 99.9 %.
- the suitable organic amine is selected from tertiary amines such as trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and A, A-dimethylcyclohexylamine; secondary amines such as dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, A-benzylmethylamine and dicyclohexylamine; primary amines such as methylamine, ethylamine, propylamine, butylamine, benzylamine, aniline, pyrrolidine, pyridine; and the like.
- tertiary amines such as trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and A, A-dimethylcyclohexylamine
- secondary amines such as dioctylamine
- the suitable acid as used in present invention is selected from hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid.
- the suitable solvents as used in any of the process steps of the present invention are selected from, but are not limited to aliphatic, alicyclic or aromatic halogenated hydrocarbons such as chlorobenzene, dichlorobenzene, dichloromethane, chloroform, tetrachloromethane, dichloroethane or trichloroethane; aromatic hydrocarbon like toluene; ethers such as diethylether, diisopropyl ether, methyl /tv7-butyl ether, methyl tert- amyl ether, dioxane, tetrahydrofuran, 1,2- dimethoxy ethane, 1 ,2-diethoxy ethane or anisole; nitriles such as acetonitrile, propionitrile, n- or iso-butyroni
- the present invention provides a process for the purification of Favipiravir which comprises converting the crude Favipiravir into a salt with an organic amine followed by treatment with a suitable acid to afford highly pure Favipiravir.
- the present invention provides a process for the purification of Favipiravir which comprises converting the crude Favipiravir into a salt with dicyclohexylamine followed by treatment with a suitable acid to afford highly pure Favipiravir.
- the pH of the reaction mixture may be adjusted to 8 to 11, e.g. > 9, such as 9 to 11, e.g. 10 to 11, e.g. by use of a base, preferably by an inorganic base, such as e.g. an alkali, e.g. a sodium and potassium or earth alkali hydroxide and carbonate, preferably a hydroxide.
- a base preferably by an inorganic base, such as e.g. an alkali, e.g. a sodium and potassium or earth alkali hydroxide and carbonate, preferably a hydroxide.
- the dicyclohexylamine salt of Favipiravir may be extracted into an organic solvent which is able to form a two-phase system with water and which is able to dissolve dicyclohexylamine, e.g.
- the present invention provides the use of Favipiravir in the form of a salt with an organic amine for the purification of a mixture of Favipiravir with impurities.
- the present invention provides the use of Favipiravir in the form of a salt with dicyclohexylamine for the purification of a mixture of Favipiravir with impurities.
- the present invention provides the use of Favipiravir in the form of a salt with morpholine for the purification of a mixture of Favipiravir with impurities.
- the purity of the crude Favipiravir is in the range of 95 to 99 %.
- the invention is further illustrated with reference to the following examples. It is apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
- the starting materials according to the present invention are known compounds that are commercially available or can be prepared in a known manner. Following examples are given by way of illustration and therefore should not be construed to limit the scope of the invention.
- the aqueous layer was slowly acidified with 20 % sulfuric acid to pH 2.0 to 2.5 to obtain a solid which was filtered, washed with water and dried to obtain pure 6-fluoro-3-hydroxypyrazine-2-carboxamide (13.85 g) (purity: 99.69 %; 88 % yield with respect to initial crude).
- Example 4 Purification of crude Favipiravir by using morpholine salt: Crude 6-fluoro-3-hydroxypyrazine-2-carboxamide (15.7 g) (purity: 95-99 %) was dissolved in acetone (75 g) at 20-25 °C. To this solution, morpholine (10.44 g) was added at 25 °C during 30 minutes. The precipitated solid was filtered, washed with acetone (20 g) and dried to obtain the Favipiravir morpholine salt (21.4 g). The obtained salt was charged in water (60 g), basified by sodium hydroxide to pH 13-14 and washed with toluene (200 g) and the toluene layer was separated.
- the aqueous layer was then slowly acidified with 20 % sulfuric acid to pH 2.0 to 2.5 to obtain a solid which was filtered and washed with water and dried to obtain pure 6-fluoro-3- hydroxypyrazine- 2-carboxamide (14.60 g) (93 % yield with respect to initial crude) (purity: >99.7 %).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an organic amine salt of Favipiravir. The present invention further discloses a process for the purification of Favipiravir, wherein purity of the obtained purified Favipiravir is in the range of 99.5 to 99.9 %.
Description
AN ORGANIC AMINE SALT OF FAVIPIRAVIR AND A PROCESS FOR THE PURIFICATION OF FAVIPIRAVIR
FIELD OF INVENTION:
The present invention relates to an organic amine salt of Favipiravir. Further, the present invention also relates to a process for the purification of Favipiravir.
BACKGROUND OF INVENTION:
Favipiravir is an anti-viral agent that selectively and potently inhibits the viral RNA-dependent RNA polymerase (RdRp). It is known under the chemical name 6-fluoro-3-hydroxy-2- pyrazinecarboxamide. Favipiravir is a compound which is useful for the treatment, such as prevention or therapy, of a viral infection or, particularly, an influenza viral infection. Favipiravir and a process for its preparation were first disclosed in W02000010569.
There are several processes disclosed in the prior art for the synthesis of Favipiravir, for instance in WO2001060834, W02000010569 and US8835636B2.
The drawback of these processes is that the purity of the obtained Favipiravir is not satisfactory, and for this reason a series of purification steps are required to provide a product which meets the high quality requirements for pharmaceutical active ingredients. Further, after the long and complex reaction sequence for the preparation of Favipiravir, a column purification is required, and therefore the overall yield of this multistep reaction is relatively low. Also, in some of the described processes for the preparation of Favipiravir mentioned in the prior art, it is not easy to isolate pure Favipiravir in high yield by a simple operation, even more since this compound is soluble in water.
Therefore, there is a need for a simple, cost-effective process which allows the preparation of highly pure Favipiravir. Accordingly, the inventors of the present invention have developed a process for the purification of Favipiravir that affords highly pure Favipiravir for further pharmaceutical use.
It has now been surprisingly found that the conversion of Favipiravir with an organic amine, results in the formation of a salt that allows a considerable decrease in the amount of impurities.
More specifically, the inventors of the present invention have found that crude Favipiravir can be converted to an organic amine salt when reacted with an organic amine. Following this procedure mostly all of the unknown impurities can be removed and the resulting Favipiravir is obtained in more than 99.6 % purity. OBJECTIVE OF INVENTION:
The main objective of the present invention is to provide an organic amine salt of Favipiravir.
Another objective of the present invention is to provide a process for the purification of Favipiravir. SUMMARY OF INVENTION:
Accordingly, the present invention provides an organic amine salt of Favipiravir.
In one embodiment, the present invention provides a process for the purification of Favipiravir comprising the steps of: a) treating crude Favipiravir with a suitable organic amine in the presence of a suitable solvent to form a corresponding organic amine salt of Favipiravir; b) isolating the organic amine salt of Favipiravir; c) treating the organic amine salt of Favipiravir of step (b) with a suitable acid to afford highly pure Favipiravir.
The organic amine is selected from tertiary amines such as trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and /V,/V-dimethylcyclohexylamine; secondary amines such as dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, /V-benzylmethylamine and dicyclohexylamine; primary amines such as methylamine, ethylamine, propylamine, butylamine, benzylamine, aniline, pyrrolidine, pyridine; and the like. In a preferred embodiment, the organic amine is selected from dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, N- benzylmethylamine and dicyclohexylamine.
The suitable solvent is selected from aliphatic, alicyclic or aromatic halogenated hydrocarbons such as chlorobenzene, dichlorobenzene, dichloromethane, chloroform, tetrachloromethane, dichloroethane or trichloroethane; aromatic hydrocarbon like toluene; ethers such as diethylether, diisopropyl ether, methyl tert- butyl ether, methyl tert- amyl ether, dioxane, tetrahydrofuran, 1,2- dimethoxy ethane, 1 ,2-diethoxy ethane or anisole; nitriles such as acetonitrile, propionitrile, n- or iso-butyronitrile or benzonitrile; amides such as /V,/V-dimethylformamide, N,N- dimethylacetamide, /V- methyl formanilide, /V-methylpyrrolidone or hexamethylphosphoric triamide; sulfoxides such as dimethyl sulfoxide or sulfones such as sulfolane; alcohols such as methanol, ethanol, isopropanol, polyethylene glycols; ketones like acetone; water, or mixtures thereof.
The suitable acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid and the like.
The purity of the crude Favipiravir is in the range of 95 to 99 %.
The purity of the obtained purified Favipiravir is in the range of 99.5 to 99.9 %. DECRIPTION OF FIGURES :
Figure 1: DSC of dicyclohexylamine salt of Favipiravir Figure 2: DSC of morpholine salt of Favipiravir DETAIFED DESCRIPTION OF THE INVENTION:
The definitions provided herein for the terminologies used in the present disclosure are for illustrative purpose only and in no manner limit the scope of the present invention disclosed in the present disclosure.
As used herein, the terms “comprises”, “comprising”, “includes”, “including”, “has”, “having”, “contains”, “containing”, “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.
The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully understood and appreciated.
In accordance with the above defined objectives, the present invention provides an organic amine salt of Favipiravir. The organic amine salt of the Favipiravir can be produced by subjecting Favipiravir to a reaction with an organic amine. This reaction is usually carried out in the presence of a suitable solvent. All types of solvents can be used for the reaction provided that their presence is not detrimental to the reaction in any way.
In a preferred embodiment, the present invention provides a dicyclohexylamine salt of Favipiravir.
In another preferred embodiment, the present invention provides a morpholine salt of Favipiravir.
In one embodiment, the present invention provides a process for the synthesis of an organic amine salt of Favipiravir, which comprises treating Favipiravir with a suitable organic amine, in the presence of a suitable solvent to afford an organic amine salt of Favipiravir.
In one embodiment, the present invention provides a process for the purification of Favipiravir comprising the steps of: a) treating crude Favipiravir with a suitable organic amine in the presence of a suitable solvent to form a corresponding organic amine salt of Favipiravir; b) isolating the organic amine salt of Favipiravir; c) treating the organic amine salt of Favipiravir of step (b) with a suitable acid to afford highly pure Favipiravir, wherein the purity of the obtained purified Favipiravir is in the range of 99.5 to 99.9 %.
The suitable organic amine is selected from tertiary amines such as trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and A, A-dimethylcyclohexylamine; secondary amines such as dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, A-benzylmethylamine and
dicyclohexylamine; primary amines such as methylamine, ethylamine, propylamine, butylamine, benzylamine, aniline, pyrrolidine, pyridine; and the like.
The suitable acid as used in present invention is selected from hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid. The suitable solvents as used in any of the process steps of the present invention are selected from, but are not limited to aliphatic, alicyclic or aromatic halogenated hydrocarbons such as chlorobenzene, dichlorobenzene, dichloromethane, chloroform, tetrachloromethane, dichloroethane or trichloroethane; aromatic hydrocarbon like toluene; ethers such as diethylether, diisopropyl ether, methyl /tv7-butyl ether, methyl tert- amyl ether, dioxane, tetrahydrofuran, 1,2- dimethoxy ethane, 1 ,2-diethoxy ethane or anisole; nitriles such as acetonitrile, propionitrile, n- or iso-butyronitrile or benzonitrile; amides such as /V,/V-dimethylformamide, N,N- dimethylacetamide, /V- methyl formanilide, /V-methylpyrrolidone or hexamethylphosphoric triamide; sulfoxides such as dimethyl sulfoxide or sulfones such as sulfolane; alcohols such as methanol, ethanol, isopropanol, polyethylene glycols; ketones like acetone; water, or mixtures thereof.
In one embodiment, the present invention provides a process for the purification of Favipiravir which comprises converting the crude Favipiravir into a salt with an organic amine followed by treatment with a suitable acid to afford highly pure Favipiravir.
In a preferred embodiment, the present invention provides a process for the purification of Favipiravir which comprises converting the crude Favipiravir into a salt with dicyclohexylamine followed by treatment with a suitable acid to afford highly pure Favipiravir.
For the extraction of the dicyclohexylamine salt of Favipiravir, the pH of the reaction mixture may be adjusted to 8 to 11, e.g. > 9, such as 9 to 11, e.g. 10 to 11, e.g. by use of a base, preferably by an inorganic base, such as e.g. an alkali, e.g. a sodium and potassium or earth alkali hydroxide and carbonate, preferably a hydroxide. The dicyclohexylamine salt of Favipiravir may be extracted into an organic solvent which is able to form a two-phase system with water and which is able to dissolve dicyclohexylamine, e.g. partially, in a two-phase system with water, including e.g. a halogenated hydrocarbon, such as methylene chloride, a ketone, such
as methyl isobutylketone and an ester of a carboxylic acid, such as ethyl acetate, isopropyl acetate, n-butyl acetate or aromatic hydrocarbon such as toluene. Water may be added to the reaction mixture, if not present in an amount sufficient to form a two phase system in the reaction mixture. According to one aspect of the present invention, the present invention provides the use of Favipiravir in the form of a salt with an organic amine for the purification of a mixture of Favipiravir with impurities.
According to another aspect of the present invention, the present invention provides the use of Favipiravir in the form of a salt with dicyclohexylamine for the purification of a mixture of Favipiravir with impurities.
According to yet another aspect of the present invention, the present invention provides the use of Favipiravir in the form of a salt with morpholine for the purification of a mixture of Favipiravir with impurities.
The purity of the crude Favipiravir is in the range of 95 to 99 %. The invention is further illustrated with reference to the following examples. It is apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention. The starting materials according to the present invention are known compounds that are commercially available or can be prepared in a known manner. Following examples are given by way of illustration and therefore should not be construed to limit the scope of the invention.
Example 1: Synthesis of a dicyclohexylamine salt of Favipiravir:
Crude 6-fluoro-3-hydroxypyrazine-2-carboxamide (15.7 g) (purity: 99.36 %) was dissolved in acetone (75 g) at 20-25 °C. To this solution, dicyclohexylamine (19.9 g) was added at 25 °C during 30 minutes. The precipitated solid was filtered, washed with acetone (10 g) and dried to obtain the Favipiravir dicyclohexylamine salt (28.7 g; purity 99.69 %; yield: 89.9 % with respect to initial crude Favipiravir).
Characterization data of the Favipiravir dicyclohexylamine salt: 'H NMR (400 MHz, DMSO-r/6): d 10.52 (s, 1H), 8.46 (broad, 1H), 7.91-7.93 (s,lH), 7.26 (s, 1H), 3.06-3.07 (m, 2H), 1.96-1.98 (m, 4H), 1.69-1.73 (m, 4H), 1.58-1.61 (m, 2H), 1.19-1.25 (m, 8H), 1.06-1.08 (m, 2H); MP 184.12 °C, Decomposition temperature 215.56 °C.
Example 2: Synthesis of a morpholine salt of Favipiravir:
Crude 6-fluoro-3-hydroxypyrazine-2-carboxamide (15.7 g) (purity: 95-99 %) was dissolved in acetone (75 g) at 20-25 °C. To this solution, morpholine (12 g) was added at 25 °C during 30 minutes. The precipitated solid was filtered and washed with acetone (20 g) and dried to give the Favipiravir morpholine salt (21 g; purity 99.7 %; yield: 93 % w.r.t. initial crude favipiravir).
Example 3: Purification of crude Favipiravir by using dicyclohexylamine salt:
Crude 6-fluoro-3-hydroxypyrazine-2-carboxamide (15.7 g) (purity: 99.36 %) was dissolved in acetone (75 g) at 20-25 °C. To this solution, dicyclohexylamine (21.85 g) was added at 25 °C during 30 minutes. The precipitated solid was filtered and washed with acetone (20 g) and dried to obtain the Favipiravir dicyclohexylamine salt (30.5 g). The obtained salt was charged in water (60 g) and basified with sodium hydroxide to pH 13-14 followed by washing with toluene (200 g) and the toluene layer was separated. The aqueous layer was slowly acidified with 20 % sulfuric acid to pH 2.0 to 2.5 to obtain a solid which was filtered, washed with water and dried to obtain pure 6-fluoro-3-hydroxypyrazine-2-carboxamide (13.85 g) (purity: 99.69 %; 88 % yield with respect to initial crude).
Characterization data of 6-fluoro-3-hydroxypyrazine-2-carboxamide: 'H NMR (400 MHz, DMSO-i/6): d 13.41 (bs, 1H), 8.75 (bs, 1H), 8.52 (bs, 1H), 8.50 (s, 1H); 13C NMR (100 MHz, DMSO-r/6): d 168.78, 159.80, 152.19, 135.96, 127.39; M/Z= 158.0 M+l; IR: 3348.98 (OH),
3219.15 ( NH), 1672.87 ( C=0), 1560.83 ( C=C), 1439.43 (NH), 1265.67 (C=N), 1231.64 ( CF), 1187.23 ( CO), 929.02 ( CH).
Example 4: Purification of crude Favipiravir by using morpholine salt: Crude 6-fluoro-3-hydroxypyrazine-2-carboxamide (15.7 g) (purity: 95-99 %) was dissolved in acetone (75 g) at 20-25 °C. To this solution, morpholine (10.44 g) was added at 25 °C during 30 minutes. The precipitated solid was filtered, washed with acetone (20 g) and dried to obtain the Favipiravir morpholine salt (21.4 g). The obtained salt was charged in water (60 g), basified by sodium hydroxide to pH 13-14 and washed with toluene (200 g) and the toluene layer was separated. The aqueous layer was then slowly acidified with 20 % sulfuric acid to pH 2.0 to 2.5 to obtain a solid which was filtered and washed with water and dried to obtain pure 6-fluoro-3- hydroxypyrazine- 2-carboxamide (14.60 g) (93 % yield with respect to initial crude) (purity: >99.7 %).
Characterization data of 6-fluoro-3-hydroxypyrazine-2-carboxamide: 'H NMR (400 MHz, DMSO-i/6): d 13.41 (bs, 1H), 8.75 (bs, 1H), 8.52 (bs, 1H), 8.50 (s, 1H); 13C NMR (100 MHz, DMSO-i/6): d 168.78, 159.80, 152.19, 135.96, 127.39; M/Z= 158.0 M+l; IR: 3348.98 (OH), 3219.15 ( NH), 1672.87 ( C=0), 1560.83 ( C=C), 1439.43 (NH), 1265.67 (C=N), 1231.64 ( CF), 1187.23 ( CO), 929.02 ( CH).
Claims
CLAIMS:
1) An organic amine salt of Favipiravir.
2) The organic amine salt of Favipiravir as claimed in claim 1 , wherein said organic amine salt is a dicyclohexylamine salt of Favipiravir or a morpholine salt of Favipiravir.
3) A process for the purification of Favipiravir comprising the steps of: a) treating crude Favipiravir with a suitable organic amine in the presence of a suitable solvent to form a corresponding organic amine salt of Favipiravir; b) isolating the organic amine salt of Favipiravir; c) treating the organic amine salt of Favipiravir of step (b) with a suitable acid to afford highly pure Favipiravir.
4) The process for the purification of Favipiravir as claimed in claim 3, wherein said organic amine is selected from tertiary amines like trimethylamine, triethylamine, tripropylamine, tributylamine, tribenzylamine and /V,/V-dimethylcyclohexylamine; secondary amines like dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, /V-benzylmethylamine and dicyclohexylamine; primary amines like methylamine, ethylamine, propylamine, butylamine, benzylamine, aniline, pyrrolidine, pyridine; and the like.
5) The process for the purification of Favipiravir as claimed in claim 4, wherein the said organic amine is selected from dioctylamine, diheptylamine, morpholine, dimethylamine, diethylamine, dipropylamine, dibutylamine, dibenzylamine, /V-benzylmethylamine, dicyclohexylamine and the like.
6) The process for the purification of Favipiravir as claimed in claim 3, wherein said suitable solvent is selected from aliphatic, alicyclic or aromatic halogenated hydrocarbons selected from chlorobenzene, dichlorobenzene, dichloromethane, chloroform, tetrachloromethane, dichloroethane or trichloroethane; aromatic hydrocarbon like toluene; ethers selected from diethylether, diisopropylether, methyl /V-butyl ether, methyl tert- amyl ether, dioxane, tetrahydrofuran, 1 ,2-dim ethoxy ethane, 1 ,2-di ethoxy ethane or anisole; nitriles selected from acetonitrile, propionitrile, n- or iso-butyronitrile or benzonitrile; amides selected from N,N- dimethylformamide, /V,/V-dimethylacetamide, /V-methyl formanilide, /V-methylpyrrolidone or hexamethylphosphoric triamide; sulfoxides selected from dimethyl sulfoxide or sulfones like
sulfolane; alcohols selected from methanol, ethanol, isopropanol, polyethylene glycols; ketones like acetone; water, or mixtures thereof.
7) The process for the purification of Favipiravir as claimed in claim 3, wherein said suitable acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid and the like.
8) The process for purification of Favipiravir as claimed in claim 3, wherein purity of the crude Favipiravir is in the range of 95 to 99 %.
9) The process for purification of Favipiravir as claimed in claim 3, wherein purity of the obtained purified Favipiravir is in the range of 99.5 to 99.9 %.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202011026193 | 2020-06-22 | ||
| IN202011026193 | 2020-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021260516A1 true WO2021260516A1 (en) | 2021-12-30 |
Family
ID=79282072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2021/055425 WO2021260516A1 (en) | 2020-06-22 | 2021-06-21 | An organic amine salt of favipiravir and a process for the purification of favipiravir |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021260516A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2192117A1 (en) * | 2007-09-27 | 2010-06-02 | Toyama Chemical Co., Ltd. | Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same |
-
2021
- 2021-06-21 WO PCT/IB2021/055425 patent/WO2021260516A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2192117A1 (en) * | 2007-09-27 | 2010-06-02 | Toyama Chemical Co., Ltd. | Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6397501B2 (en) | N-[(3-aminooxetane-3-yl) methyl] -2- (1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl) -6-methyl-quinazoline- Process for the preparation of 4-amine | |
| WO2018025722A1 (en) | Method for producing intermediate of biotin and method for producing biotin | |
| JP2021504418A (en) | Method for producing 2- (5-methoxyisochroman-1-yl) -4,5-dihydro-1H-imidazole and its hydrogen sulfate | |
| JP2023171763A (en) | 2-indolinone derivatives known as intermediate for production of nintedanib | |
| US20150119570A1 (en) | Process of preparing alcaftadine | |
| IL276483B2 (en) | Continuous process for the preparation of trazodone | |
| WO2021260516A1 (en) | An organic amine salt of favipiravir and a process for the purification of favipiravir | |
| US7541494B2 (en) | Process for the manufacture of iohexol | |
| JP2019507156A (en) | Process for producing 4-alkoxy-3-hydroxypicolinic acid | |
| JP2009143918A (en) | Deprotection of n-boc compound | |
| JP4594938B2 (en) | Method for preparing gabapentin | |
| AU2010299484A1 (en) | Polymorphs of sorafenib acid addition salts | |
| JP2018024643A (en) | Method for producing intermediate of biotin, and method for producing biotin | |
| WO2022220231A1 (en) | Method for isolating fluorinated substance | |
| JP2004315535A (en) | Method for preparing hexahydropyridazine-3-carboxylic acid derivative | |
| JPWO2017195619A1 (en) | Method for producing a nitrobenzene compound | |
| EP0729948B1 (en) | The production of 3-alkylamino-2-piperazinylpyridines | |
| US11180441B2 (en) | Method for preparing substituted 4-aminoindane derivatives | |
| US20220194977A1 (en) | New process for preparing sugammadex | |
| WO2016135616A1 (en) | An improved process for the preparation of bisoprolol and its intermediate | |
| JP6797839B2 (en) | New manufacturing method of teriflunomide | |
| JP2007521224A (en) | Method for purification and isolation of RAC-bicalutamide | |
| WO2021019310A1 (en) | Process for the preparation of luliconazole | |
| EP0561994B1 (en) | Process for the preparation of 2-(2-bromo-2-nitroethenyl)furan | |
| WO2022241188A1 (en) | Enantioselective synthesis of aminotropane compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21829549 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21829549 Country of ref document: EP Kind code of ref document: A1 |